



PARTIEL LCC3 – December 2022

4 HEURES / 4 HOURS

Cours:

Financial Communication

NOM DU PROFESSEUR

Marc SIMON

Allowed documents : Yes

Allowed Internet : Yes

Barème / Scoring : 100%



SUJET / SUBJECT :

Oxford Biomedica is a leading, fully integrated, gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford Biomedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology, CNS disorders, liver diseases and respiratory disease. The Group has also entered into a number of partnerships, including with Novartis, Bristol Myers Squibb, Sanofi, Axovant Gene Therapies, Orchard Therapeutics, Santen, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 550 people.

You have just been hired by John Dawson, CEO of Oxford Biomedica. You are required to present a Financial Communication Analysis of Oxford Biomedica to Stuart Paynter CFO of Oxford Biomedica in 4 hours. Please analyse carefully the following data provided to you, hereafter.

For further information please log on Annual Report 2020-2021 on https://www.obx.com/system/files/financial-reports/annual-reports/OXB_AR21_final.pdf

Advice: Owing to the fact that you only have 4 hours, it is strongly recommended to focus on the major aspects and matrices presented during the course.